Oppenheimer Reiterates Outperform on Praxis Precision Medicine, Maintains $134 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $134.
August 14, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Praxis Precision Medicine and maintained a price target of $134.
The reiteration of an Outperform rating and a high price target of $134 by a reputable analyst from Oppenheimer is likely to positively influence investor sentiment and drive short-term price appreciation for PRAX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100